Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Substitution for Benzodiazepines in MDD or GAD
NCT01244711Phase 4Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2008
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of quetiapine in major depressive disorder (MDD) and generalized anxiety disorder (GAD), sponsored by Weill Cornell Medicine. Primary endpoints: Montgomery Asberg Depression Rating Scale at 12 weeks, Hamilton Anxiety Rating Scale at 12 weeks and 1 more. Started Sep 2008; status: terminated.
02
Drugs
quetiapine
03
Conditions
major depressive disorder (MDD)generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT01244711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01244711.